Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRTP-102
- Development stage
- Preclinical
- Lead developer
- CellinCells
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies
- Administration
- Intraarticular
01
Overview
TRTP-102 is an injectable organoid-based regenerative therapy being developed by CellinCells for the treatment of osteoarthritis and meniscus damage. Utilizing the company's proprietary Tissue-Regenerative Therapeutic Platform (TRTP), the therapy involves the delivery of three-dimensional organoids directly into the joint. These organoids are designed to mimic the native tissue architecture and biological function of cartilage and meniscus, facilitating more effective tissue repair and regeneration compared to traditional single-cell therapies. TRTP-102 aims to address the underlying structural damage in joint diseases, potentially restoring mobility and reducing pain for patients.
Beyond the preview
Go deeper on TRTP-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRTP-102.